Literature DB >> 2968268

Comparison of the antihypertensive effects of celiprolol and acebutolol.

D Terziivanov1, V Vlahov, N Belovezhdov, Z Gerova.   

Abstract

The antihypertensive effects of the new cardioselective beta-blocker celiprolol and acebutolol have been compared. Thirty patients with arterial hypertension WHO Grade I-II were treated in a double-blind fashion with celiprolol or acebutolol. Before starting the treatment and on Days 15 and 29, before the morning dose, blood samples were taken for measurement of the plasma level of celiprolol. At the same times physical examinations, and clinical and urine chemistry analyses were performed. At the 99% probability level both drugs had significantly lowered the systolic and diastolic blood pressures to normal values at the end of the second and fourth weeks. There was no significant difference between their antihypertensive efficacy. The decrease in diastolic blood pressure at the end of the second week was significantly correlated with the reciprocal of the plasma celiprolol concentration at steady-state at the end of the dosage interval.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968268     DOI: 10.1007/bf00614547

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  Celiprolol: a new beta adrenoceptor antagonist with novel ancillary properties.

Authors:  T P Pruss; A Khandwala; P S Wolf; P Grebow; L Wong
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  Celiprolol in the treatment of hypertension: a comparison with propranolol.

Authors:  S H Taylor; A Beattie; B Silke
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  A pharmacokinetic evaluation of celiprolol in healthy elderly volunteers.

Authors:  R J Norris; E H Lee; D Muirhead; S W Sanders
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

4.  A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension.

Authors:  B Silke; F Rosenthal; S Taylor
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

5.  Mathematical modelling accounting for discrepancies between blood levels and pharmacodynamic effects of a drug. Application to the numerical optimization of tertatolol.

Authors:  Y Cherruault; J F Prost; I Karpouzas; M Hotchen
Journal:  Int J Biomed Comput       Date:  1986-05

6.  Celiprolol: pharmacokinetics and duration of pharmacodynamic activity.

Authors:  F S Caruso; H D Doshan; P H Hernandez; R Costello; W Applin; E S Neiss
Journal:  Br J Clin Pract Suppl       Date:  1985-06

7.  Specific and sensitive assay of celiprolol in blood, plasma and urine using high-performance liquid chromatography.

Authors:  J N Buskin; R A Upton; F Sörgel; R L Williams; E Lang; L Z Benet
Journal:  J Chromatogr       Date:  1982-07-09

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

  8 in total
  3 in total

Review 1.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 2.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 3.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.